CDH6 Antibody Epitope Targeting for Tumor Cell Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant unmet clinical need for CDH6-targeted drugs to treat ovarian and kidney cancer, as current treatments are limited and no drugs have been approved for marketing.
Innovation Solution
Development of an antibody or antigen-binding fragment specifically binding to CDH6, particularly targeting the EC1, EC1-EC2, EC2, EC2-EC3, EC3, EC4, or EC5 regions of the CDH6 protein, with endocytic activity, and potentially conjugated to therapeutic agents or tracers, to treat tumors such as ovarian and kidney cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDH6-targeted drugs are developed, then treatment effectiveness for ovarian and kidney cancer is improved, but currently no drugs have been approved for marketing indicating lack of viable therapeutic options
Solution Approach 1:
The patent segments the CDH6 protein into multiple epitope regions (EC1, EC1-EC2, EC2, EC2-EC3, EC3, EC4, EC5) and develops antibodies targeting each specific segment. This segmentation allows for multiple antibody variants to be created, increasing the likelihood of finding a viable therapeutic that can be manufactured and approved, thereby resolving the contradiction between treatment effectiveness and drug development status.
Solution Approach 2:
The patent employs parameter changes by creating antibodies with different binding specificities against various epitope regions of CDH6. By varying the target region parameters (different EC regions), the invention generates a portfolio of antibody candidates with potentially different therapeutic profiles, improving the chances of developing an approved drug while maintaining treatment effectiveness.
2Measurement precision
If an antibody specifically binds to CDH6, then binding specificity and therapeutic potential are improved, but the complexity of developing and characterizing multiple antibody variants increases
Solution Approach 1:
The patent divides the CDH6 antigen into discrete epitope segments (EC1, EC1-EC2, EC2, EC2-EC3, EC3, EC4, EC5) and develops specific antibodies for each segment. This segmentation strategy provides clear measurement criteria for binding specificity while organizing the complexity into manageable categories of antibody variants based on their target regions.
Solution Approach 2:
The patent creates a universal antibody development platform that can target multiple epitope regions of CDH6 using a standardized approach. This multi-functional framework allows the same development methodology to be applied across different antibody variants, reducing the overall complexity of characterizing and developing the full portfolio of CDH6-targeting antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody or antigen-binding fragment specifically binds to CDH6, demonstrating good binding activity and internalization capability, offering a promising therapeutic approach for ovarian and kidney cancer.
Implementation Method 1
The present disclosure provides an antibody or an antigen-binding fragment specifically binding to CDH6
Implementation Method 2
the antibody or the antigen-binding fragment has endocytic activity
Data Source
Figure 1~4
Figure 5~7
Figure 8~10
AI summary
Provided are an antibody specifically binding to cadherin 6 (CDH6) and a use thereof. Specifically disclosed are murine and humanized antibodies binding to CDH6, preparation methods therefor, and uses thereof. The antibodies have good affinity with CDH6 protein and a better endocytic activity, and thus can be applied to the preparation of drugs for treating tumors and the like.